Anti-diabetic Drugs and Fatty Liver Management

NCT05041673 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether certain anti-diabetic medications can help manage fatty liver disease in adults with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 120 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2021-02 · est. completion 2022-09

Where 1 site · Egypt

What this study is testing ClinicalTrials.gov NCT05041673 ↗

Description as written by the study sponsor.

Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%). Until now there is no well-established treatment for fatty liver disease. Study setting: Randomized controlled trial Study population: Patients with type 2 DM plus Fatty Liver. Arms and Interventions 1\. Experimental arms: Group 1: metformin +/- insulin +/- sulfonylurea Group 2: Metformin plus vildagliptin+/- insulin +/- sulfonylurea Group 3: Metformin plus liraglutide+/- insulin+/- sulfonylurea Group 4: Metformin plus empagliflozin +/- insulin +/- sulfonylurea

Treatments tested

Metformin also known as Liraglutide, empagliflozin, Vildagliptin Drug

Antidiabetic drugs

Main thing measured	Change in steatosis as measured using CAP score (fibroscan) and MRI
Sponsor	Alexandria University
Conditions studied	Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05041673 ↗